Ann: SubB2M/CA15.3 Clinical Validation Data Investor Presentation, page-43

I asked Bard what it thought about the l;ikelihood of commercial success for IIQ is - given these test results...

Sure. Inoviq Ltd. (ASX:IIQ) recently announced that it had received positive results from an independent clinical validation study of its SubB2M/CA15-3 test for breast cancer detection. The study showed that the test had high accuracy (87%), sensitivity (81%), and specificity (93%), outperforming a leading CA15-3 test.The positive results from the clinical validation study are a significant milestone for Inoviq. The test is now one step closer to commercialization, and the company is planning to submit the test for regulatory approval in the United States and Europe.The likelihood of commercial success for the SubB2M/CA15-3 test is high. The test has the potential to be a valuable tool for early breast cancer detection, and there is a large market for such a test. The global market for breast cancer diagnostics is estimated to be worth over $10 billion, and it is expected to grow at a compound annual growth rate of 5.7% from 2022 to 2028.However, there are some challenges that Inoviq will need to overcome in order to achieve commercial success for the SubB2M/CA15-3 test. The company will need to secure regulatory approval for the test in the United States and Europe. The company will also need to develop a commercialization strategy for the test, and it will need to raise additional capital to fund the commercialization of the test.Overall, the likelihood of commercial success for the SubB2M/CA15-3 test is high. The test has the potential to be a valuable tool for early breast cancer detection, and there is a large market for such a test. However, Inoviq will need to overcome some challenges in order to achieve commercial success for the test.Here are some additional factors that could affect the likelihood of commercial success for the SubB2M/CA15-3 test:The cost of the testThe reimbursement policies of insurance companiesThe competitive landscapeThe success of other early breast cancer detection testsIt is important to note that the commercial success of the SubB2M/CA15-3 test is not guaranteed. However, the positive results from the clinical validation study are a significant milestone for Inoviq, and the company is well-positioned to achieve commercial success for the test.Sourcesinfo